Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $12.40.

Several equities research analysts recently issued reports on the stock. HC Wainwright dropped their target price on shares of Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating on the stock in a report on Monday. Royal Bank of Canada reduced their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. Oppenheimer cut their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, November 18th. Finally, JMP Securities reissued a “market outperform” rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new position in Inovio Pharmaceuticals during the 2nd quarter valued at $661,000. Rhumbline Advisers lifted its position in shares of Inovio Pharmaceuticals by 5,943.0% during the second quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 37,857 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 12,100 shares during the period. Cornercap Investment Counsel Inc. bought a new position in shares of Inovio Pharmaceuticals in the second quarter worth about $184,000. Finally, Dimensional Fund Advisors LP purchased a new position in Inovio Pharmaceuticals in the 2nd quarter worth about $605,000. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO opened at $1.87 on Friday. The firm has a market capitalization of $48.81 million, a P/E ratio of -0.90 and a beta of 0.84. Inovio Pharmaceuticals has a one year low of $1.74 and a one year high of $14.75. The company’s 50-day simple moving average is $3.35 and its 200 day simple moving average is $6.05.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.